Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
about
Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated MalignanciesCervical cancer prevention in Australia: Planning for the futureCharacterizing Twitter Discussions About HPV Vaccines Using Topic Modeling and Community DetectionHPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital dataCost analysis of Human Papillomavirus-related cervical diseases and genital warts in SwazilandHuman papillomavirus vaccination: the population impact.Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.Papillomaviruses: Viral evolution, cancer and evolutionary medicineAssociation Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern BrazilCervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.Associations Between Exposure to and Expression of Negative Opinions About Human Papillomavirus Vaccines on Social Media: An Observational StudyRoutine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness AnalysisEstimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in AustraliaHuman Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursHuman Papillomavirus Laboratory Testing: the Changing ParadigmRacial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerPopulation-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Prophylactic HPV vaccination: past, present, and future.Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia.Cervical cancer control in Latin America: A call to action.The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer.Overview of the benefits and potential issues of the nonavalent HPV vaccine.Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates.Willingness of reproductive-aged women in a Nigerian community to accept human papillomavirus vaccination for their children.Y Chromosome DNA in Women's Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study.Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus.Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.Mothers' and their daughters' use of preventive measures against cervical cancer.
P2860
Q26770541-D881C1B6-1E87-4DE4-951E-175B7EEF3E11Q28270412-C74F1F1A-19F4-4D5F-8844-8F553C414295Q28595890-A8EED6EF-6640-468A-95F9-825A9BFCA516Q31038776-009B5BFD-E8BA-4DEE-8969-7F87F1595CEBQ31041736-8E5AE215-6431-48C7-9472-95E202CA2EC0Q33713018-3C28CCAA-DA31-414F-8DEC-F7DB9BF485BBQ33806566-80082C5C-E0B4-448E-9134-FF5DF58F2125Q34736619-6BB41B65-F6D3-4943-8992-1B449D392F25Q35166924-F3AE3019-3539-42E9-B481-DB880240B70DQ35691927-195CBAC1-F5E0-4CD1-93A7-81FEF83376A9Q35908482-9BA0B1C6-99D0-4B70-B4DE-E4891FC6D485Q35922347-74462F61-01CB-4A17-A595-59B37A8B967CQ35957814-4BB85794-A161-4143-A310-45ED90511464Q35991580-EF39A63C-D65E-48BC-9C4F-C312B43E240FQ36066822-42F7DFB4-8EBA-4A23-B58A-6958A13A169AQ36114517-897695A1-5D4F-434E-A09F-CC8C9622B765Q36251151-AA97BBD2-6089-4F79-A019-327F3D0C9E0CQ36418117-959A7987-89F1-4853-80CF-49DAF9EBA8B4Q36638606-C277690B-A455-4A51-A799-A358B30F30A3Q36675236-1FF26EAB-1DCF-446E-954E-BE333377A703Q37014050-77A017E3-5E6E-41BE-A290-89279098FF17Q37135163-EF385BF5-8859-4C1E-A8B6-085F5E55770BQ37288157-6756463C-3C73-4847-98DF-82468A05C45AQ37840047-8EBEC265-C201-4475-B678-01155541645AQ38373388-8D037B33-0606-4171-B2F8-62DBE442561AQ38586257-4FDDC491-7617-4D0D-A905-5F36902A4D1BQ38597567-9390EC5B-FC6F-49A5-800A-DF1E89201DD9Q38599579-AB54C52C-4742-49B6-B09B-98C94A938982Q38655636-82531476-4E5A-44E8-8146-4599060FE2D0Q38670183-7C41560E-F1BE-4F29-BF54-1CB141F811A0Q38723059-0F6F8BB7-75FD-4503-A9A2-CB110AB3E3AEQ38770473-36ECBDD7-8E2F-4E16-B6C5-919B811EE0B4Q38807434-6F8D0807-AAEC-4DD1-9B4B-56E92899D1E3Q39268883-702ADA04-9833-4E2C-BAFC-168F96F852DAQ40056191-AA5834D0-C803-491D-925E-E0A658ED53ECQ40569845-15AFB2E9-8FA7-4F58-8E85-7F820C299830Q40675275-64BB1A9C-7C49-430D-B2C1-E7810F7F796DQ40805660-F5343410-BE13-485F-A01E-82116FA134E8Q41035560-6DDB4AAC-1420-4CA0-8436-4AF5F96A9ED5Q41286222-FE767EAF-055B-43A9-98E2-FDAC7AFD35AE
P2860
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Assessment of herd immunity an ...... a repeat cross-sectional study
@ast
Assessment of herd immunity an ...... a repeat cross-sectional study
@en
Assessment of herd immunity an ...... a repeat cross-sectional study
@nl
type
label
Assessment of herd immunity an ...... a repeat cross-sectional study
@ast
Assessment of herd immunity an ...... a repeat cross-sectional study
@en
Assessment of herd immunity an ...... a repeat cross-sectional study
@nl
prefLabel
Assessment of herd immunity an ...... a repeat cross-sectional study
@ast
Assessment of herd immunity an ...... a repeat cross-sectional study
@en
Assessment of herd immunity an ...... a repeat cross-sectional study
@nl
P2093
P50
P3181
P1476
Assessment of herd immunity an ...... a repeat cross-sectional study
@en
P2093
Eleanor Cummins
John M Kaldor
Julia M L Brotherton
Kathleen McNamee
Maria Garefalakis
Michael Malloy
Sepehr N Tabrizi
Suzanne M Garland
P304
P3181
P356
10.1016/S1473-3099(14)70841-2
P407
P577
2014-10-01T00:00:00Z